Julio Rosenstock, MD, and Juan Frias, MD, were featured prominently throughout the American Diabetes Association (ADA) 83rd Scientific Sessions. The prolific researchers also had findings simultaneously published in the New England Journal of Medicine and The Lancet.
Dr. Rosenstock is the lead investigator for Novo Nordisk’s ONWARDS 1 program exploring the first investigational once-weekly insulin. “In ONWARDS 1, insulin icodec allowed people to spend significantly more Time in Range, with comparable Time below Range vs. once-daily basal insulin glargine U100,” said Dr. Rosenstock. “A once-weekly basal insulin has the potential to change how we treat people with type 2 diabetes needing basal insulin replacement.”
Trial results were presented at the ADA sessions and published in NEJM. Novo Nordisk announced that a biologics license application for the insulin icodec has been submitted for FDA review.
Dr. Rosenstock was also an author of the recently published NEJM article, Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
Dr. Frias is the lead author for Eli Lily’s Phase 2 trial for orforglipron for type 2 diabetes. A potential alternative to injectable GLP-1 receptor agonists and oral semaglutide, oral orforglipron could offer a more convenient — and easier to manufacture — treatment option to people with type 2 diabetes. “It’s a chemical, a small molecule that also acts on the GLP-1 receptor, but because it’s not a protein it’s not degraded by enzymes,” said Dr. Frias. “Earlier pharmacokinetic studies have shown that taking it with or without food doesn’t make a difference.”
This research could lead to a more convenient and accessible treatment option. Trial results were presented at the ADA sessions and published in The Lancet.
Dr. Frias was also an author of the following articles recently published by NEJM:
- Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
- Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Julio Rosenstock, MD: ADA 83rd Scientific Sessions Recap
Presentations
- Effect of Oral Nonpeptide GLP-1 Receptor Agonist Orforglipron (LY3502970) in Participants with Obesity or Overweight—A Phase 2 Study
- Improved A1C and TIR with Once-Weekly Insulin Icodec vs. Insulin Glargine U100 in Insulin Naïve T2D—ONWARDS 1
Symposia
- Transforming Therapy with Ultra-Long-Acting Insulins (Chair)
- Oral Semaglutide for Treatment of Obesity and Type 2 Diabetes—Results from OASIS 1 and PIONEER PLUS Trials; OASIS 1 Trial Design and Baseline Characteristics
- Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon Receptor Triagonist—Obesity, NAFLD, and T2D Phase 2 Trial Results; Retatrutide T2D—Efficacy and Safety Results of the 36-Week T2D Phase 2 Trial
Posters
- N-Terminal Pro-B Type Natriuretic Peptide Concentrations in Diabetic Cardiomyopathy—Baseline Data from the ARISE-HF Trial
- Duration of Sustained Weight Loss in Clinical Trials Evaluating Tirzepatide vs. Comparators—An Exploratory Analysis of SURPASS 1–5
- “SURPASS(ing)” an Era of Basal-Bolus Insulin Therapy—Tirzepatide vs. Insulin Lispro TID Added-on to Poorly Controlled Basal Insulin-Treated in Type 2 Diabetes
- Longer Time Spent in Glycemic Control after Initiating Tirzepatide vs. Comparators—Exploratory Analysis of SURPASS 1–5 Trials
- Consistent Glycemic Efficacy and Safety of Concomitant Use of iGlarLixi and Sodium–Glucose Cotransporter-2 Inhibitor Therapy for Type 2 Diabetes—A Patient-Level Pooled Analysis
- Predictors of Glycemic Control in Older People with Type 2 Diabetes Treated with iGlarLixi—A Pooled Analysis
- Predictors of Achieving Target HbA1c <7% in People with Type 2 Diabetes Advancing Treatment with iGlarLixi
- Predictors of Glycemic Control by Derived Time in Range for People with Type 2 Diabetes Advancing with iGlarLixi—A Pooled Analysis
- Predictors of HbA1c and dTIR Responses with iGlarLixi in Type 2 Diabetes—Patient-Level Exploratory Analyses of the LixiLan-L Trial
- The Face of Diabetic Cardiomyopathy—Baseline Characteristics from the ARISE-HF Trial
Juan Frias, MD: ADA 83rd Scientific Sessions Recap
Presentations
- Efficacy and Safety of Coadministered s.c. Semaglutide and s.c. Cagrilintide in Type 2 Diabetes
- Effect of Coadministered s.c. Semaglutide and s.c. Cagrilintide on Glycemic Levels Measured by CGM
Symposia
- SURMOUNT 2 Trial Results and Potential Role of Tirzepatide in Treating Obesity in Type 2 Diabetes; SURMOUNT 2—Rationale, Hypotheses, and Study Design
- Transforming Therapy with Ultra-Long-Acting Insulins; Rationale and Proof-of-Concept
Posters
- “SURPASS(ing)” an Era of Basal-Bolus Insulin Therapy—Tirzepatide vs. Insulin Lispro TID Added-on to Poorly Controlled Basal Insulin-Treated in Type 2 Diabetes
- Effect of Orforglipron vs. Placebo and Dulaglutide on Glycemic Control and Body Weight in Patients with Type 2 Diabetes
- Tirzepatide Reduces HbA1c and Body Weight Significantly More than Placebo or Semaglutide Irrespective of Baseline Beta-Cell Function—Post Hoc Analysis from SURPASS-1 and SURPASS-2
- Predictors of Achieving Target HbA1c <7% in People with Type 2 Diabetes Advancing Treatment with iGlarLixi
- Predictors of Glycemic Control by Derived Time in Range for People with Type 2 Diabetes Advancing with iGlarLixi—A Pooled Analysis
- Predictors of HbA1c and dTIR Responses with iGlarLixi in Type 2 Diabetes—Patient-Level Exploratory Analyses of the LixiLan-L Trial
- Once Weekly (QW) Basal Insulin Fc (BIF) and Daily Degludec (DEG) Achieve Comparable Glycemic Control in Three Patient Populations Studied during Phase 2—Clinical Insights from CGM Assessments
- Initiation of Once-Weekly (QW) Basal Insulin Fc (BIF) in Three Patient Populations in Phase 2 Studies Using a One-Time Loading Dose (LD) Minimizes Transient Hyperglycemia and Is Not Associated with Excess Hypoglycemia Risk vs. Degludec
- Uncovering Root Causes Contributing to Persistent Gaps in Glycemic Control and Effective Weight Management in Patients with Type 2 Diabetes and Obesity
